Gregg W. Stone

Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial

BACKGROUND: The BRIGHT-4 trial (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4) demonstrated that procedural anticoagulation with bivalirudin plus a high-dose postprocedure infusion reduced the 30-day composite end point of all-cause death...

Lipid Burden and Efficacy of Preventive PCI of Vulnerable Atherosclerotic Coronary Plaques: Post Hoc Analysis From the PREVENT Trial

BACKGROUND: Preventive percutaneous coronary intervention (PCI) of non–flow-limiting lesions (fractional flow reserve >0.80) that are high-risk plaques has emerged as a potential strategy to reduce cardiac events. However, identifying which lesions derive the greatest benefit fro...

One vs twelve month aspirin after percutaneous coronary intervention for acute myocardial infarction: individual patient-data analysis of TARGET-FIRST and ULTIMATE-DAPT trials

Giuseppe Tarantini, Xiaojuan Zhang, Luca Nai Fovino, Jing Kan, Zhen Ge, Guillaume Cayla, Pieter C Smits, Benjamin Honton, Valeria Paradies, Yann Poezevara,